Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 10


AACR Cancer Progress Report 2015.

Baselga J, Bhardwaj N, Cantley LC, DeMatteo R, DuBois RN, Foti M, Gapstur SM, Hahn WC, Helman LJ, Jensen RA, Paskett ED, Lawrence TS, Lutzker SG, Szabo E.

Clin Cancer Res. 2015 Oct 1;21(19 Suppl):S1-128. doi: 10.1158/1078-0432.CCR-15-1846. No abstract available.


Disparities in cervical cancer mortality rates as determined by the longitudinal hyperbolastic mixed-effects type II model.

Tabatabai MA, Kengwoung-Keumo JJ, Eby WM, Bae S, Guemmegne JT, Manne U, Fouad M, Partridge EE, Singh KP.

PLoS One. 2014 Sep 16;9(9):e107242. doi: 10.1371/journal.pone.0107242. eCollection 2014.


Toll-like receptors and prostate cancer.

Zhao S, Zhang Y, Zhang Q, Wang F, Zhang D.

Front Immunol. 2014 Jul 23;5:352. doi: 10.3389/fimmu.2014.00352. eCollection 2014. Review.


Therapeutic cancer vaccines: past, present, and future.

Guo C, Manjili MH, Subjeck JR, Sarkar D, Fisher PB, Wang XY.

Adv Cancer Res. 2013;119:421-75. doi: 10.1016/B978-0-12-407190-2.00007-1. Review.


High HPV-51 prevalence in invasive cervical cancers: results of a pre-immunization survey in North Sardinia, Italy.

Piana A, Sotgiu G, Cocuzza C, Musumeci R, Marras V, Pischedda S, Deidda S, Muresu E, Castiglia P.

PLoS One. 2013 May 22;8(5):e63395. doi: 10.1371/journal.pone.0063395. Print 2013.


Virus-like particles for the prevention of human papillomavirus-associated malignancies.

Wang JW, Roden RB.

Expert Rev Vaccines. 2013 Feb;12(2):129-41. doi: 10.1586/erv.12.151. Review.


Human papillomavirus infection in a male population attending a sexually transmitted infection service.

Álvarez-Argüelles ME, Melón S, Junquera ML, Boga JA, Villa L, Pérez-Castro S, de Oña M.

PLoS One. 2013;8(1):e54375. doi: 10.1371/journal.pone.0054375. Epub 2013 Jan 23.


Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy.

Vacchelli E, Galluzzi L, Eggermont A, Fridman WH, Galon J, Sautès-Fridman C, Tartour E, Zitvogel L, Kroemer G.

Oncoimmunology. 2012 Sep 1;1(6):894-907.


Parental acceptance of HPV vaccine in Peru: a decision framework.

Bartolini RM, Winkler JL, Penny ME, LaMontagne DS.

PLoS One. 2012;7(10):e48017. doi: 10.1371/journal.pone.0048017. Epub 2012 Oct 29.


Achieving high coverage in Rwanda's national human papillomavirus vaccination programme.

Binagwaho A, Wagner CM, Gatera M, Karema C, Nutt CT, Ngabo F.

Bull World Health Organ. 2012 Aug 1;90(8):623-8. doi: 10.2471/BLT.11.097253. Epub 2012 May 23.

Supplemental Content

Support Center